For example, docetaxel-based therapy prolongs OS for just 3 months, and Androgen Receptor (AR) antagonist enzalutamide showed only a 5-month survival advantage in patients with metastatic PC [3,4]. The gene discussed is AR; the disease is pachyonychia congenita.